CHOSOURCE™ GS KO cell line: optimization, improvement strategy, and case study

The CHOSOURCE™ expression platform, consisting of the GS KO cell line, ADCC+ cell line, and TnT Transposon technology, has a proven track record within the industry with over 100 licenses signed worldwide. This is in part due to its flexibility to bring forward different types of biotherapeutics including antibodies, bispecifics, fusion proteins, vaccines, and novel scaffolds, as well as being applied to a wide variety of disease areas such as oncology, neurodegenerative, cardiovascular, and auto-immune.

With the platforms benefits and track record, Sanyou Bio's leveraged the CHO GS KO for the development of high expression stable production cell lines and enhance their bioprocess through molecular design, screening, and process optimization strategies.

Watch this webinar to learn:

• The benefits and applications of the CHOSOURCE platform
• How to improve protein expression from all perspectives of molecular design
• Efficient cell line development through optimizing and different screening strategies
• How to optimize the process parameters to the quality attributes of different antibodies

The CHOSOURCE Platform is available for research, clinical, diagnostic, and commercialization applications, including services, under specific licenses from Revvity.